Cumulatively, these challenges are multifaced and highlight the need for a concerted strategy that integrates rational design, tumor biology knowledge, and sophisticated manufacturing to comprehensively unlock the therapeutic potential of albumin-based nanomedicines in TNBC. This evidence concerns the gene ALB and neoplasm.